The risk of losing income increases dramatically within a few years after the onset of neuromyelitis optica spectrum disorder (NMOSD) in patients positive for antibodies against aquaporin-4 (AQP4), compared with the general population. That’s according to a nationwide study in Denmark that also showed AQP4-related NMOSD was strongly associated…
News
Combining blood-cleaning therapies such as plasma exchange or immunoadsorption with standard steroid treatment can improve recovery outcomes in patients having an attack of neuromyelitis optica spectrum disorder (NMOSD), a study that reported no significant safety concerns shows. The study, “Efficacy and safety of apheresis therapy in AQP4 antibody‐positive…
Nearly all neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) are free of relapses after six months, according to interim data from an ongoing post-marketing surveillance study in Japan. With a relapse rate of only 5% over six months, the findings were “comparable or lower…
Age at disease onset and sex ratio — the ratio of males to females — among people with neuromyelitis optica spectrum disorder (NMOSD) are influenced by the proportion of cases with antibodies against aquaporin-4 (AQP4). That’s according to a review study from an international team of researchers that sheds…
Neuromyelitis optica spectrum disorder (NMOSD) patients whose first symptoms affect the brainstem, which is the bottommost part of the brain, are frequently misdiagnosed and experience higher rates of relapses, according to a two-center study in China. Data also showed about half of these patients initially experienced uncontrollable nausea, vomiting,…
Immunosuppressive therapy significantly reduces relapses in elderly people with late-onset neuromyelitis optica spectrum disorder (NMOSD), with more than half of patients becoming relapse-free, a retrospective study in South Korea has found. Treatment also eased or stabilized disability for most patients, without a marked risk of severe infections, and was…
Treatment with rituximab significantly reduces the risk of relapse and lessens disability in neuromyelitis optica spectrum disorder (NMOSD) patients with antibodies against aquaporin-4 (AQP4), according to a long-term, retrospective Australian study. Most of the analyzed patients received an initial infusion of rituximab at 1,000 mg, given as two separate…
Enspryng (satralizumab-mwge) promotes an anti-inflammatory profile in plasmablasts, the immune cells that produce large amounts of the self-reactive antibodies that drive most cases of neuromyelitis optica spectrum disorder (NMOSD). That’s according to a study analyzing immune cells from NMOSD patients before and after treatment with Enspryng, as well…
The circulating levels in the blood of six inflammatory proteins may help predict the risk of relapse and severe attacks in people with neuromyelitis optica spectrum disorder (NMOSD), a study from China reports. Four of these inflammation-related proteins — FGF-23, DNER, GDNF, and SLAMF1 — were used to build…
Long-term treatment with Uplizna (inebilizumab) was well tolerated and led to sustained disease control for adults with neuromyelitis optica spectrum disorder (NMOSD). That’s according to final data from the open-label extension period of the Phase 2/3 N-MOmentum clinical trial (NCT02200770), top-line data of which supported the therapy’s…
Recent Posts
- Immune cell traps may worsen NMOSD attacks, study finds
- Simple blood test may help guide personalized NMOSD treatment
- Life with NMOSD is a game I never asked to play, but keep winning
- Treatment linked to fewer NMOSD relapses, less steroid use in study
- Navigating NMOSD at the intersection of culture and family